New drug combo aims to shrink spleen in Hard-to-Treat myelofibrosis

NCT ID NCT07447817

Not yet recruiting Disease control Sponsor: John Mascarenhas Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests two oral drugs, selinexor and pacritinib, in 26 adults with myelofibrosis who have anemia and low platelets and have not taken JAK inhibitors before. The main goal is to see if the combination can shrink the spleen by at least 35%. The study also tracks symptom improvement and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: selinexor and pacritinib (two oral drugs)
What this could lead to: If it works, this could offer a new treatment option for myelofibrosis patients who cannot take standard JAK inhibitors due to low blood counts.
What could go wrong: This is a small, early-phase trial with only 26 participants. The combination may cause side effects or fail to shrink the spleen enough. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anemia myelofibrosis primary myelofibrosis thrombocytopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOFIBROSIS POST POLYCYTHEMIA VERA MYELOFIBROSIS POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS

Contacts and locations

Locations

Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States
The University of Kansas Cancer Center-Westwood

Westwood, Kansas, 66205, United States
Wake Forest Baptist Health Comprehensive Cancer Center

Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.